|
Collados-Ros A, Muro M, Legaz I. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review. Biomedicines. 2024 Jan 17;12(1):208. doi: 10.3390/biomedicines12010208. PubMed PMID: 38255313; PubMed Central PMCID: PMC10813452.
AÑO: 2024; IF: 3.9
|
38255313
|
Legaz I, Navarro-Noguera E, Collados-Ros A, Bolarin JM, Muro M. Biomarkers of Innate Immunity and Immunological Susceptibility to Viral Infection in Patients with Alcoholic Cirrhosis. Biomedicines. 2024 Feb 1;12(2):336. doi: 10.3390/biomedicines12020336. PubMed PMID: 38397937; PubMed Central PMCID: PMC10887413.
AÑO: 2024; IF: 3.9
|
|
Botella C, Galian JA, Jimenez-Coll V, Fernandez-Gonzalez M, Morales F, Martinez-Gomez G, Gonzalez-Lopez R, Alegria MJ, Moya MR, Martinez-Banaclocha H, Minguela A, Legaz I, Llorente S, Muro M. Early Monitoring of Donor-Derived Cell-Free DNA in Kidney Allograft Recipients Followed-Up for Two Years: Experience of One Center. Life (Basel). 2024 Nov 16;14(11):1491. doi: 10.3390/life14111491. PubMed PMID: 39598289; PubMed Central PMCID: PMC11595986.
AÑO: 2024; IF: 3.2
|
|
Legaz I, Jimenez-Coll V, Gonzalez-Lopez R, Fernandez-Gonzalez M, Alegria-Marcos MJ, Galian JA, Botella C, Moya-Quiles R, Muro-Perez M, Minguela A, Llorente S, Muro M. MicroRNAs as Potential Graft Rejection or Tolerance Biomarkers and Their Dilemma in Clinical Routines Behaving like Devilish, Angelic, or Frightening Elements. Biomedicines. 2024 Jan 5;12(1):116. doi: 10.3390/biomedicines12010116. PubMed PMID: 38255221; PubMed Central PMCID: PMC10813128.
AÑO: 2024; IF: 3.9
|
|
Legaz I, Muro M. Natural Killer Cells and Their Implications in Immune Response Diversification in Clinical Pathology and Neoplastic Processes. Int J Mol Sci. 2023 Apr 24;24(9):7743. doi: 10.3390/ijms24097743. PubMed PMID: 37175450; PubMed Central PMCID: PMC10178591.
AÑO: 2023; IF: 4.9
|